Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Corporate Investor Presentation

Rigel Corporate Investor Presentation

Date	Title
10/18/19	Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authorization Application
10/16/19	Rigel to Host Investor and Analyst Call on October 23, 2019 Call will feature presentation by key opinion leader in the treatment of chronic ITP SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced that it will host a conference call and webcast for investors and analysts on Wednesday,
10/02/19	Rigel Secures Credit Facility for Up to $60 Million Receives $9 million in payments from collaborations SOUTH SAN FRANCISCO , Oct. 2, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap").

Stock Quote

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume
Data as of

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site

Investors

Investors

Corporate Profile

Corporate Investor Presentation

Stock Quote

Stock Chart

E-mail Alerts